文献速递心脑血管急症消化、代谢与肾脏急症

阿帕贝特联合标准治疗对近期急性冠脉综合征合并2型糖尿病患者主要不良心血管事件的影响:一项随机临床试验

Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者中,阿帕贝特100 mg每日两次口服未显著降低主要不良心血管事件风险(HR 0.82,95%CI 0.65-1.04,P=0.11)。

该随机、双盲、安慰剂对照试验在13个国家190个中心纳入2425例近期(7-90天内)发生急性冠脉综合征、合并2型糖尿病且高密度脂蛋白胆固醇水平低的患者,按1:1随机接受阿帕贝特100 mg口服每日两次(n=1215)或匹配安慰剂(n=1210),均联合标准治疗。主要终点为心血管死亡、非致死性心肌梗死或卒中首次发生的复合终点。中位随访26.5个月,阿帕贝特组主要终点发生125例(10.3%),安慰剂组149例(12.4%),HR 0.82(95%CI 0.65-1.04),P=0.11,未达统计学显著。阿帕贝特组因肝酶升高停药35例(2.9%),安慰剂组11例(0.9%)。

要点

  • 在近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者中,阿帕贝特100 mg口服每日两次联合标准治疗未显著降低主要不良心血管事件(HR 0.82,95%CI 0.65-1.04,P=0.11)。
  • 中位随访26.5个月,阿帕贝特组主要终点发生125例(10.3%),安慰剂组149例(12.4%)。
  • 阿帕贝特组停药114例(9.4%),安慰剂组69例(5.7%);因肝酶升高停药分别为35例(2.9%)与11例(0.9%)。
  • 该研究纳入标准为急性冠脉综合征发生在前7至90天内、合并2型糖尿病且高密度脂蛋白胆固醇水平低。

适用人群与场景

  • 近期(前7至90天内)发生急性冠脉综合征、合并2型糖尿病且高密度脂蛋白胆固醇水平低的患者。

处置流程与药物剂量

  • 阿帕贝特100 mg口服每日两次,联合标准治疗,疗程至研究随访结束(中位随访26.5个月)。
  • 匹配安慰剂口服每日两次,联合标准治疗。

研究设计与关键结果

  • 随机、双盲、安慰剂对照试验,在13个国家190个中心开展,纳入2425例患者(平均年龄62岁,女性618例[25.6%]),2320例(95.7%)完成主要终点 ascertainment。
  • 主要终点为心血管死亡、非致死性心肌梗死或卒中首次发生的复合终点;中位随访26.5个月,阿帕贝特组125例(10.3%) vs 安慰剂组149例(12.4%),HR 0.82(95%CI 0.65-1.04),P=0.11,未达统计学显著。
  • 阿帕贝特组停药114例(9.4%) vs 安慰剂组69例(5.7%);因肝酶升高停药分别为35例(2.9%) vs 11例(0.9%)。

证据类型、等级与局限

  • 证据类型:随机、双盲、安慰剂对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于近期急性冠脉综合征合并2型糖尿病及低高密度脂蛋白胆固醇患者,在标准治疗基础上加用阿帕贝特100 mg口服每日两次未显著降低主要不良心血管事件风险(HR 0.82,95%CI 0.65-1.04,P=0.11)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Bromodomain and extraterminal proteins are epigenetic regulators of gene transcription. Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis. Pooled phase 2 data suggest favorable effects on clinical outcomes.

OBJECTIVE: To test whether apabetalone significantly reduces major adverse cardiovascular events.

DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial, conducted at 190 sites in 13 countries. Patients with an acute coronary syndrome in the preceding 7 to 90 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollment, which started November 11, 2015, and ended July 4, 2018, with end of follow-up on July 3, 2019.

INTERVENTIONS: Patients were randomized (1:1) to receive apabetalone, 100 mg orally twice daily (n = 1215), or matching placebo (n = 1210) in addition to standard care.

MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke.

RESULTS: Among 2425 patients who were randomized (mean age, 62 years; 618 women [25.6%]), 2320 (95.7%) had full ascertainment of the primary outcome. During a median follow-up of 26.5 months, 274 primary end points occurred: 125 (10.3%) in apabetalone-treated patients and 149 (12.4%) in placebo-treated patients (hazard ratio, 0.82 [95% CI, 0.65-1.04]; P = .11). More patients allocated to apabetalone than placebo discontinued study drug (114 [9.4%] vs 69 [5.7%]) for reasons including elevations of liver enzyme levels (35 [2.9%] vs 11 [0.9%]).

CONCLUSIONS AND RELEVANCE: Among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02586155.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Ray KK, Nicholls SJ, Buhr KA, et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2020. PMID: 32219359. doi:10.1001/jama.2020.3308

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。